By Jordan Xu, Managing Director, DROFEN Machinery
Summary:
An injection pen assembly User Requirements Specification (URS) can contain a detailed speed target, station list and automation requirement while leaving the most important project interfaces unresolved. What exactly arrives at the line? Which specifications govern it? Who approves changes? How does a failed inspection become a physical rejection and an electronic record?
These questions matter whether a pharmaceutical manufacturer purchases pre-assembled pens and installs a final assembly line, or a device manufacturer builds the empty mechanism using pre-assembly equipment. They should be answered before equipment design is frozen-not left for the first production trial.
In a recent ONdrugDelivery Expert View on fragmented procurement and integrated assembly, I examined the risks that emerge between separately supplied machines, controls and qualification packages. The practical next step is to turn integration intentions into written interface requirements.
Start with the manufacturing route
Pre-assembly produces an empty pen mechanism from its component parts. Final assembly brings a filled cartridge or another specified primary container together with a suitable pre-assembled device, using a process developed for that product presentation.
A pharmaceutical company buying pre-assembled pens does not automatically need its own pre-assembly machine. Its project may instead focus on incoming-device acceptance, filled-container handling, final assembly, inspection and downstream packaging. Conversely, a device supplier producing empty mechanisms needs to control the mechanical output that the downstream process will receive.
The URS should therefore define the manufacturing route, incoming material state and outgoing product state. It should also identify operations outside the equipment scope, such as sterile filling or a separate packaging process. A transfer in trays or batches needs different arrangements from a direct conveyor interface; both need agreed material identification and acceptance rules.
The output target also needs a shared baseline: product mix, material availability, changeover assumptions and the relationship between upstream and downstream capacity. Jordan Xu's PharmTech discussion of fill-finish and pen-assembly capacity bottlenecks explains why the nominal speed of an individual machine is not enough to define sustainable output. The URS should identify the conditions under which the required output will be assessed.
Interface 1: Device and container specifications
The device supplier, container supplier and equipment team need a common understanding of the drawings, revisions, permitted tolerances and sample materials used for development. A nominal cartridge volume or pen-family name is not enough to define the assembly process.
The interface record should describe the relevant contact surfaces, fixture datums, seating features, permitted handling forces and critical geometric relationships. The teams should identify which characteristics are measured on incoming material and which are verified during assembly.
Representative development samples should cover justified variations, not only one ideal batch. The purpose is to learn whether the process remains suitable across the agreed input range. It is not to assume that every individual dimension can drift independently without affecting the assembled product.
Jordan Xu's PharmTech analysis of pen injector pre-assembly variability discusses why component orientation and dimensional relationships matter upstream. That remains relevant when the customer buys an already assembled empty pen: the upstream process still defines the downstream input.
For teams translating these characteristics into station and inspection requirements, the DROFEN engineering guide to selecting and implementing pen injector pre-assembly equipment provides the more detailed equipment-selection perspective. The interface review should identify which characteristics must remain controlled when an empty mechanism is handed to the next process.
Interface 2: Inspection result and physical product status
An inspection decision is useful only if the system associates it with the correct product and performs the required action. Before design freeze, define how the line identifies a unit or nest, how the result follows it between stations, and how the system confirms removal of a rejected unit.
The team should also agree what happens when a result is missing, a unit is removed manually, a reject confirmation fails or the machine is interrupted. These are not instructions to scrap every unit automatically. They are situations requiring a documented, risk-based handling and restart strategy.
For final assembly, a force–displacement result may help identify an assembly process outside its approved window. Its relationship to physical defects and functional performance must be established through appropriate development and testing. A curve alone is not a universal substitute for dimensional checks or finished-device verification.
The PharmTech article on cartridge press-fit in final assembly provides the process-level background. The interface question is how the result becomes a reliable product-status decision.
The corresponding equipment-planning questions-container handling, critical assembly stations and verification scope-are developed in the DROFEN engineering guide to pen injector final assembly systems. Together, these discussions help distinguish a process-monitoring capability from the requirements needed to implement it within a specific line.
Interface 3: Equipment records and the customer's quality system
Specify which records are needed, how they are used and where they are retained. Relevant fields may include material lot, unit or nest identity, recipe revision, inspection result, parameter changes, timestamps and operator actions. The appropriate detail depends on the intended process and record requirements.
Where electronic records fall within the applicable scope, technical functions and operating procedures should be assessed together. FDA's Part 11 scope-and-application guidance does not make every automated system a Part 11 system simply because it is installed in a pharmaceutical facility.
Agree how data transfer will be tested, how a failed transfer will be detected, and how records will be retrieved after backup or restoration. If a reusable pallet identifier is involved, define how the record remains distinguishable after the same pallet carries another product. For batch-fed devices, agree the lot relationship across incoming materials and the assembly batch.
Interface 4: Changes after the agreed baseline
Device and material specifications may evolve. The project needs an agreed way to assess changes in components, formulations of materials, packaging format, inspection criteria and equipment configuration.
Document who can approve each change, which teams must review it and what evidence is needed before implementation. A supplier's acceptance of a changed part does not automatically establish that the downstream assembly process remains suitable. Equally, adjusting an equipment setting should not silently change a product acceptance criterion.
Interface 5: Testing responsibilities and evidence
The URS should lead to a traceable test plan. Identify which interfaces can be challenged during factory acceptance testing (FAT), which require the customer's actual site systems during site acceptance testing (SAT), and how accepted evidence will be used within the qualification programme.
Simulated signals can support development when a downstream machine is unavailable, but a simulated handshake should not be presented as proof of an untested live interface. Document the limitation and retain the remaining site verification task.
Useful challenges include a known non-conforming input, a missing inspection result, a failed reject confirmation, an interrupted data transfer and a controlled restart. Select them through the project risk assessment. FAT and SAT support equipment acceptance; they do not independently establish every aspect of product validation or batch release.
A practical design-freeze review
Before approving the equipment concept, the teams should be able to answer five questions:
*Are the incoming device and container specifications revision-controlled and agreed?
*Is ownership assigned for each material, inspection and data interface?
*Are abnormal events and product-status decisions defined?
*Is there a documented route for assessing changes?
*Can each important interface requirement be connected to planned acceptance evidence?
If an answer is unclear, the project still has an engineering decision to make. More detailed machinery specifications will not resolve an unassigned interface.
Applying the discussion to a DROFEN project
DROFEN Machinery provides injection pen pre-assembly equipment and injection pen final assembly equipment. It can also offer a coordinated injection pen supply and final assembly equipment solution, subject to device suitability and an agreed project scope.
For an initial scope discussion, the useful starting point is the intended presentation, incoming device and container state, annual output requirement and current design-freeze status. Confidential drawings and detailed technical files can be considered under agreed disclosure arrangements rather than published online.
For the broader process overview, see The Complete Technical Guide to Injection Pen Assembly Lines. To discuss the device–equipment interface for a specific programme, contact DROFEN with the non-confidential project scope.
About the author
Jordan Xu is Managing Director of DROFEN Machinery. His technical writing examines injection pen assembly, process inspection, manufacturing data integrity and qualification planning. His contributions to ONdrugDelivery can be found on the publisher's Jordan Xu author page.